He Y G, Mellon J, Niederkorn J Y
Department of Ophthalmology, University of Texas Southwestern Medical Center at Dallas, Texas 75235-057, USA.
Transplantation. 1996 Mar 27;61(6):920-6. doi: 10.1097/00007890-199603270-00014.
The present study examined the potential of orally induced tolerance for preventing immunological rejection of corneal allografts. Orthotopic corneal allografts were transplanted from either C3H (MHC + multiple minor H-mismatched) or NZB (multiple minor H-mismatched only) donors to CB6F1 recipients on day 0. Tissue cultured corneal epithelial and endothelial cells from relevant donor strains were administered orally from day -14 to day -4 on a daily basis, The incidence of graft rejection, graft mean survival time (MST), and alloimmune responses, and the antigen specificity of induced tolerance were studied. Oral immunization induced a remarkable tolerance such that only 55% of the orally immunized hosts rejected their fully allogeneic corneal grafts (MST = 43 days) compared with 100% rejection (MST = 18 days) in normal controls. Likewise, rejection of MHC-matched, multiple minor H-mismatched corneal grafts fell from 80% in untreated controls to 36% in orally immunized hosts. Oral immunization was effective in desensitizing previously immunized hosts. Rejection of MHC-matched, multiple H minor-mismatched corneal allografts fell from 93% in preimmune, unfed hosts to 36% in preimmune, orally tolerized mice. Thus, oral immunization is a safe and effective method for desensitizing high-risk, preimmune hosts and promoting corneal allograft survival.
本研究检测了口服诱导耐受预防角膜同种异体移植免疫排斥反应的潜力。在第0天,将原位角膜同种异体移植物从C3H(MHC + 多个次要组织相容性抗原不匹配)或NZB(仅多个次要组织相容性抗原不匹配)供体移植到CB6F1受体。从第-14天至第-4天,每天口服给予来自相关供体品系的组织培养角膜上皮细胞和内皮细胞。研究了移植排斥反应的发生率、移植物平均存活时间(MST)、同种免疫反应以及诱导耐受的抗原特异性。口服免疫诱导了显著的耐受,使得口服免疫的宿主中只有55%排斥其完全同种异体的角膜移植物(MST = 43天),而正常对照中的排斥率为100%(MST = 18天)。同样,MHC匹配、多个次要组织相容性抗原不匹配的角膜移植物的排斥率从未经治疗的对照中的80%降至口服免疫宿主中的36%。口服免疫在使先前免疫的宿主脱敏方面是有效的。MHC匹配、多个次要组织相容性抗原不匹配的角膜同种异体移植物的排斥率在免疫前未喂食的宿主中为93%,而在免疫前口服耐受的小鼠中降至36%。因此,口服免疫是使高风险、免疫前宿主脱敏并促进角膜同种异体移植存活的一种安全有效的方法。